Stablecoins are here to stay says BlackRock
LONDON - LivaNova PLC (NASDAQ:LIVN), a leader in medical technology with annual revenues of $1.3 billion, has shared promising 24-month data from their CORE-VNS study, indicating sustained benefits of Vagus Nerve Stimulation (VNS) Therapy™ for patients with drug-resistant epilepsy (DRE) experiencing generalized tonic-clonic (GTC) seizures. While the company posted negative earnings in the last twelve months, InvestingPro analysts expect profitability to return this year, with projected earnings of $3.67 per share. Published in the journal Epilepsia, the study reveals a median seizure reduction of 77% and reports that 43% of participants achieved seizure freedom at the 24-month mark.
The CORE-VNS study is a comprehensive evaluation of VNS Therapy in over 800 epilepsy patients across 61 global sites. It represents the largest dataset on the therapy’s effectiveness to date. The company maintains a strong financial position with a healthy current ratio of 1.58 and operates with a moderate debt level, according to InvestingPro data, which shows over 30 additional key financial metrics and insights available for subscribers. Participants, many of whom were diagnosed before the age of 18 and had a median epilepsy duration of 10 years, showed a significant decrease in GTC seizure frequency, with a median reduction of 52% as early as the three-month visit.
Ana Suller Marti, M.D., Assistant Professor of Neurology at Western University and lead author of the study, emphasized the importance of these findings for clinicians, given the severity and debilitating nature of GTC seizures. The study also noted that patients had previously tried a median of six anti-seizure medications, with some having attempted up to 20, underscoring the challenge of treating this condition.
Despite the positive outcomes, it’s important to note that VNS Therapy has not been approved by the U.S. Food and Drug Administration (FDA) for primary generalized seizures, and its safety and effectiveness in reducing such seizures have not been established. The study did report typical adverse events associated with VNS Therapy device placement, including dysphonia, cough, and neck pain.
LivaNova’s commitment to advancing epilepsy treatment is reflected in their ongoing efforts to publish 36-month outcomes from the CORE-VNS study. The company continues to partner with physicians and transparently communicate scientific data, as stated by Stephanie Bolton, LivaNova President, Global Epilepsy. With a market capitalization of $2.4 billion and an impressive gross profit margin of 69%, LivaNova demonstrates strong operational efficiency. InvestingPro analysis suggests the stock is currently undervalued, presenting a potential opportunity for investors. For comprehensive insights and detailed financial analysis, including the company’s extensive Pro Research Report, visit InvestingPro.
This article is based on a press release statement and provides an overview of the latest findings from the CORE-VNS study on VNS Therapy in patients with drug-resistant epilepsy.
In other recent news, LivaNova PLC reported first-quarter earnings that surpassed analyst expectations, with adjusted earnings per share reaching $0.88, compared to the consensus of $0.76. The company’s revenue for the quarter was $317 million, exceeding the expected $302 million and marking an 8.9% growth on a constant currency basis. Following these results, LivaNova raised its full-year 2025 revenue growth guidance to 6-7% on a constant currency basis, while adjusting its EPS guidance to $3.60-$3.70 due to external factors like the SNIA impact and tariffs. Wolfe Research upgraded LivaNova’s stock rating to Outperform, setting a price target of $60, citing improved valuation and resolution of legal issues in Italy. Jefferies also raised its price target for LivaNova from $74 to $79, maintaining a Buy rating, driven by strong performance in the Heart-Lung Machine segment and the Neuro division outside the U.S. Additionally, LivaNova is seeking reconsideration for Medicare coverage of its Vagus Nerve Stimulation Therapy for treatment-resistant depression, based on positive data from the RECOVER study. Meanwhile, the company faces a $360 million liability following an Italian Supreme Court decision related to environmental damages, which it plans to contest. These developments reflect a dynamic period for LivaNova, with significant financial and legal activities unfolding.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.